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Abstract
Background Excellent results have been reported with mini-
gastric bypass. We adopted and modified the one-anastomosis
gastric bypass (OAGB) concept. Herein is our approach, re-
sults, and long-term follow-up (FU).
Methods Initial 1200 patients submitted to laparoscopic
OAGB between 2002 and 2008 were analyzed after a 6–12-
year FU. Mean age was 43 years (12–74) and body mass
index (BMI) 46 kg/m2 (33–86). There were 697 (58 %) with-
out previous or simultaneous abdominal operations, 273
(23 %) with previous, 203 (17 %) with simultaneous, and 27
(2 %) performed as revisions.
Results Mean operating time (min) was as follows: (a) prima-
ry procedure, 86 (45–180); (b) with other operations, 112 (95–
230); and (c) revisions, 180 (130–240). Intraoperative compli-
cations led to 4 (0.3 %) conversions. Complications prompted
operations in 16 (1.3 %) and were solved conservatively in 12
(1 %). Long-term complications occurred in 12 (1 %). There
were 2 (0.16 %) deaths. Thirty-day and late readmission rates
were 0.8 and 1 %. Cumulative FU was 87 and 70 % at 6 and
12 years. The highest mean percent excess weight loss was
88 % (at 2 years), then 77 and 70 %, 6 and 12 years postop-
eratively. Mean BMI (kg/m2) decreased from 46 to 26.6 and
was 28.5 and 29.9 at those time frames. Remission or im-
provement of comorbidities was achieved in most patients.
The quality of life index was satisfactory in all parameters
from 6 months onwards.
Conclusions Laparoscopic OAGB is safe and effective. It re-
duces difficulty, operating time, and early and late complica-
tions of Roux-en-Y gastric bypass. Long-term weight loss,
resolution of comorbidities, and degree of satisfaction are sim-
ilar to results obtained with more aggressive and complex
techniques. It is currently a robust and powerful alternative
in bariatric surgery.
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Introduction
Obesity has become one of the fastest-growing and greatest
health problems in both developed and developing countries
[1]. Morbid obesity (MO) leads to complications affecting
nearly every organ system and a decrease in life expectancy
as well [2]. Operative treatment is the most effective therapy
available for MO. It enhances durable excess weight loss
(EWL), eliminates (or ameliorates) comorbidities, improves
quality of life (QoL), and lengthens life span [3]. The increas-
ing demand for bariatric surgery (BS) has encouraged many
digestive surgeons and laparoscopic experts to enter the field.
Today, alternatives range from Bsimple^ restrictive models to
Bcomplex^ operations that radically alter gastrointestinal (GI)
structure and function.
Laparoscopic mini-gastric bypass (MGB) was proposed as
a simple and effective treatment for MO [4]. After two de-
cades performing both open and laparoscopic BS, we adopted
the MGB concept but developed adjustments to counteract its
major criticism (namely alkaline reflux and its consequences).
In our original publication [5], the term Bone-anastomosis
gastric bypass (OAGB)^ was coined for this modified proce-
dure. This study aimed to evaluate experience and long-term
follow-up (FU) in a large cohort of patients withMO in whom
laparoscopic OAGB was performed at a single institution.
Patients and Methods
This is a retrospective review of a prospectively maintained
database of 1200 consecutive patients with MO submitted to
laparoscopic OAGB from July 2002 to October 2008. This
comprises the initial part of our series, and data was analyzed
after all patients completed a FU of 6 to 12 years. Patient
inclusion was according to criteria by the National Institutes
of Health Development Panel (body mass index (BMI)
>40 kg/m2 or BMI >35 kg/m2 with severe related comorbid-
ity) [6]. In agreement with current recommendations, patients
with class I obesity and metabolic comorbidities were also
included [7]. Ideal body weight was determined according to
Metropolitan Life Insurance Company 1983 height/weight ta-
bles [8]. Excess weight (EW) was defined as the difference
between a patient’s weight and the theoretical medium-frame
ideal body weight. The percent of EW lost (%EWL), change
in mean BMI, and mean percent of excess BMI lost
(%EBMIL: ini t ia l BMI − current BMI / ( ini t ia l
BMI − 25) * 100) were used to evaluate weight loss (WL)
[9]. Reinhold’s classification was used to define the effect of
BS. Good and excellent results (EWL > 50%)were defined as
successful treatment [10]. Remission of comorbidities was
considered when no medications and/or support were needed,
and improvement when these latter decreased in number and/
or dosing; this was corroborated clinically and/or biochemi-
cally. Written informed consent was obtained from all pa-
tients. The study was conducted after approval from the ethics
committee and Institutional Review Board.
Preoperative Assessment and Work-Up
Candidates were evaluated by a multidisciplinary medical unit
and underwent preoperative psychological, nutritional, and
comprehensive medical evaluations. A thorough assessment
was performed of their general condition, associated illnesses,
risk factors, mental status, motivations for BS, and ability to
adhere to a postoperative regimen. Biochemical and radiolog-
ical studies (abdominal ultrasound, chest x-ray, upper GI se-
ries), as well as endocrine and cardiopulmonary assessment,
were performed. Supplementary tests related to existing co-
morbidities were carried out accordingly. Patients underwent
respiratory physiotherapy and were encouraged to do physical
exercise. In order to lose at least 10 % (20 % for BMI >50 kg/
m2) of their EWpreoperatively, theywere submitted to 12 days
of an 800-cal/day pure high-protein diet with micronutrients
and vitamins (Vegefast-Complet®-Vegenat, Spain) followed
by a complete liquid diet 5 to 7 days prior to operation. This
was part of a prospective randomized controlled trial (RCT)
comparing Vegefast-Complet® to a natural high-protein diet
performed at our center [11]. Antithrombotic and antibiotic
prophylaxis were given to all patients.
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Operative Technique
All procedures were performed by a single surgeon (MC)
and essentially the same surgical team. The patient is
placed in a modified lithotomy position with the surgeon
standing between the patient’s legs, the camera operator on
the right side, and an assistant on the left. Six trocars are
normally used (Fig. 1). OAGB is diagrammatically shown
in Fig. 2. The first step consists of locating the Treitz liga-
ment and measuring the jejunal loop to be bypassed which
initially was ∼200 cm. After publishing results of our first
209 patients [5], we started to measure the whole small
bowel (SB) routinely (Treitz to ileocecal valve), to deter-
mine the extent of bypassed SB (afferent limb) and com-
mon channel (efferent limb); we select the midportion and
thus their lengths are usually similar (from ∼250 to
350 cm). For increasing BMIs, we add 10–50 cm of
bypassed SB (with no specific formula) but always main-
tain at least ∼250–300 cm of common channel. Therefore,
the extent of bypassed SB was based on total SB length and
BMI for the last ∼1000 patients in this series. The patient is
then placed in a 30° anti-Trendelenburg position. The angle
of His is identified and the fat pad at the esophago-gastric
(EG) junction explicitly dissected in order to visualize the
diaphragm’s left crus for optimal endostapler positioning at
this critical location. With associated hiatal hernia (very
common in MO), this step includes section of peri-
esophageal adhesions and phreno-esophageal ligament to
reduce the hernia. Hiatal closure is performed selectively
(marked enlargement). An automated camera-holding sys-
tem (Lap Man®-Medsys, Belgium) is then installed and
operated through a laser remote control (Lapstick®-
Medsys, Belgium). Ultrasound shears (Autosonix®-
Covidien, USA) are used to section the lesser gastric cur-
vature’s fat and blood vessels at the level of the crow’s foot
to enter the lesser sac. An endoscopic stapler loaded with a
45-mm/3.5-mm cartridge (Endo-GIA®-Covidien, USA) is
inserted through the created opening and applied, section-
ing the stomach horizontally. A 36-Fr double-lumen
orogastric tube (Ref 340.36®, Vygon, France) is inserted
to calibrate the gastric reservoir. Fatty tissue and fibrous
adhesions between the posterior gastric wall and pancreas
are dissected. Then, an endoscopic stapler loaded with 60-
mm/3.5-mm cartridges (Endo-GIA®-Covidien, USA) is
consecutively applied (usually three times), sectioning the
stomach vertically and completing the gastric reservoir.
The latter should be long, narrow, well vascularized, and
easy to move caudally. The orogastric tube is removed and
the previously chosen SB mobilized upward placing it
without tension in an antecolic, antegastric position.
Bivalving of omentum is especially required in superobese
patients and those with central obesity. A continuous
reabsorbable no. 2-0 suture (Polisorb®-Covidien, USA) is
sewn in a latero-lateral position, securing the SB loop to the
gastric reservoir’s staple line along ∼8–10 cm. Enterotomy
and gastrotomy (distal reservoir) are done with ultrasound
shears. An endoscopic stapler loaded with a 30-mm/3.5-
mm cartridge (Endo-GIA®-Covidien, USA) is partially
inserted (∼75 %) and applied between both, thus creating
a gastroenteric anastomosis ∼2–2.5 cm long. Incisions on
the anterior anastomotic wall are sutured with reabsorbable
no. 2-0 (Polisorb®-Covidien, USA) interrupted stitches.
These are also used to fix the (afferent) biliopancreatic
(BP) SB loop in an upward direction (∼8–10 cm) to the
excluded stomach, and also the common (efferent) SB loop
to the excluded gastric antrum. These measures unload
anastomotic tension, improve its orientation, and reinforce
the antireflux mechanism. Anastomosis integrity is verified
with a pneumatic test. Fibrin glue (Tissucol®-Baxter, USA)
or surgical glue (Glubran 2 ®-Gem, Italy) is applied to the
anastomotic surface and stapled regions of the gastric res-
ervoir and remnant, and the greater omentum is tucked and
adhered to them. Lastly, a penrose drain is positioned under
the left hepatic lobe and brought out through the 5-mm
right subcostal incision.
Fig. 1 Sites for trocar placement in laparoscopic one-anastomosis gastric
bypass which include one 10 mm (camera), two 12 mm (surgeon’s oper-




An upper GI hydrosoluble contrast swallow (Gastrografin®-
Bracco Diagnostics, Canada) was routinely performed the
morning after to verify patency, rule out leaks, and provide a
baseline postoperative Bmap.^ The urine catheter was re-
moved and the patient actively mobilized. A clear liquid diet
was then started with swallows of ∼30 ml. The patients usu-
ally tolerated this regimen well, their drain was removed, and
they were discharged ∼24 h postoperatively with specific in-
dications regarding diet, activities, and medications. The drain
was left in place and removed at the first office visit only in
patients with unusual operative bleeding, a higher risk for
postoperative bleeding (i.e., liver failure), and complex oper-
ative cases (i.e., reoperations and revisional BS).
Medium- and Long-Term Follow-Up
Postoperative FU office visits for clinical and complete bio-
chemical evaluation including macro- and micronutrients
were scheduled 3, 6, 12, 18, and 24 months after BS, and
yearly thereafter. In between these time frames, we kept close
contact through telephone or e-mail. Due to our described
referral pattern, we strove to keep an updated web page which
included a blog and forum where patients could retrieve all
kinds of information and maintain communication with any
member of our team and with other patients as well. In regard
to our electronic reports for our Bremote^ FU, concerning
measurements and WL, we have tried to be as objective as
possible and thus these include front and side full-length
photographs with waist and hip measurements, and weight
(either from an electronic scale report with name or a patient’s
photo on a bathroom scale); moreover, the electronic FU re-
port contains all information which would be evaluated during
an in-office consultation including GI status, side effects and
development of complications, eating and exercise habits, use
of medications and supplements, and complete biochemical
reports.
The patients followed a nutritional protocol designed at our
center. Intestinal adaptation was usually completed within the
first 3 months; however, the process could take up to 6 months
or more, especially in cases of frequent dietary transgressions.
From the 6th month onwards, the patients usually tolerated all
kinds of food. They were administered proton pump inhibitors
(PPIs) and sucralfate daily (first month), high-protein powder
and calcium (first 3 months), and a daily mineral-vitamin sup-
plement (first year), with maintenance doses recommended
for life. Specific mineral and/or nutritional supplements were
prescribed as needed for documented deficiencies (some
starting even in the preoperative period).
Gastrointestinal and Quality of Life Evaluation
Postoperative endoscopic (control) studies were planned for
all patients completing a 5-year FU as well as for those refer-
ring persistent upper GI symptoms. Along with preoperative
psychological evaluations, a QoL baseline assessment was
applied using the Impact of Weight on QoL (IWQoL) survey
[12]; this latter was repeated at periodic postoperative office
visits and/or included in the electronic Bremote^ FU report.
Fig. 2 Diagrammatic
representation of the one-
anastomosis gastric bypass with
gastric pouch (∼15 cm) and
latero-lateral anastomosis. The
afferent loop is suspended 8–
10 cm above the anastomosis.




Demographics and Operative Data
There were 744 female (62 %) and 456 male (38 %) patients
with a mean age of 43 years (range, 12–74). Mean preopera-
tive BMI was 46 kg/m2 (range, 33–86) and mean preoperative
EW was 65 kg (range, 34–220). Our cohort was composed of
different subgroups which included 697 patients (58 %) with
no previous or simultaneous abdominal operations (subgroup
1). Another 273 (23 %) had had prior open abdominal opera-
tions and thus required adhesiolysis of variable complexity,
and a total of 203 (17%) had abdominal operations performed
simultaneously, particularly gallbladder removal and/or hiatal
or ventral hernia repairs (subgroup 2). Finally, in 27 (2 %),
laparoscopic OAGB was performed as a revision of other
(failed) bariatric procedures (subgroup 3) including previous
laparoscopic gastric bands (n = 13), as well as open vertical
banded gastroplasties (n = 14). Perioperative results are shown
in Table 1. Operative time (OT) varied among different sub-
groups. Mean length of stay (LOS) was significantly lower for
patients without complications. Other results demonstrating
quick patient recovery are outlined, as well as a summary of
overall morbidity and mortality (further specified in Table 2).
Noteworthy is the fact that we did not reoperate or have a
record of any reoperation elsewhere for failure of the
procedure.
Morbidity and Mortality
Complications and side effects are depicted in Table 2.
Conversions to an open approach due to intraoperative prob-
lems and open reoperations due to immediate early complica-
tions were all performed through a left subcostal mini-
laparotomy (LSML); this has been described elsewhere [13],
and we utilized it routinely in the open bariatric era [14].
Intraoperative complications requiring conversion to an open
approach occurred in four patients (0.3 %). Intra-abdominal
hemorrhage was not adequately controlled by laparoscopic
means in two; bleeding was from a gastric reservoir’s artery
in one and from a ruptured vein in the posterior gastric wall in
the other. The remaining two cases included one EG junction
perforation by the calibration tube and one incorrect gastric
transection in a patient with severe cardio-esophageal inflam-
mation; both were related to technical difficulty during our
learning curve and required conversion to distal Roux-en-Y
gastric bypass (RYGB) with esophago-ileal anastomosis.
Early major complications requiring reoperations occurred
in 16 patients (1.3 %) and included intra-abdominal bleeding
(9), leaks (3), and early SB obstruction (SBO) (2). Rare com-
plications included necrosis of excluded anterior gastric wall
in one patient and acute dilation of excluded stomach in an-
other. The former was in a patient with a BMI >70 who re-
quired a tracheostomy for intubation; the tube was displaced
and severe abdominal pain developed few hours after the op-
eration. Re-laparoscopy disclosed extensive necrosis of ex-
cluded stomach which was resected through LSML. In the
other patient, excluded stomach and afferent limb were
completely filled with BP secretion. Re-laparoscopy ruled
out SBO and verified anastomosis integrity. Decompression
was obtained through a nasogastric tube positioned into the
afferent loop (removed upon the patient’s discharge) and a
gastrostomy tube (removed on an ambulatory basis).
Successful conservative treatment of early major complica-
tions was achieved in 12 patients (1 %), including leaks
(10), acute pancreatitis (1), and infected hematoma (1).
Late complications included 6 stomal stenosis (0.5 %), 4
successfully treated through endoscopic dilation (single ses-
sion) ∼2 to 3 months after operation. Another patient (lost to
FU) was submitted at another hospital to repeated dilations
and suffered a perforation that required urgent operative treat-
ment. A further patient required a temporary prosthesis due to
failed endoscopic treatments performed elsewhere 2 years af-
ter the initial operation. A total of 6 patients (0.5%) developed
anastomotic or marginal ulcers (MU); 5 were acute and pre-
sented without warning signs or symptoms with upper GI
bleeding. Another presented more chronically with persistent
Table 1 Overall perioperative characteristics of 1200 morbidly obese
patients submitted to laparoscopic one-anastomosis gastric bypass
(OAGB)
Variable OAGB (n = 1200)
Mean (range) operative time (min)
Subgroup 1 86 (45–180)
Subgroup 2 112 (95–230)
Subgroup 3 180 (130–240)
Mean (range) length of stay
Uncomplicated patients (97.4 %) 24 h (15–120)
Complicated patients (2.6 %) 9 days (5–32)
Postoperative course
Flatus passage 24–48 h
Analgesic use 24–36 h
CPAP/BiPAP needsa 24–72 h
Need for PPIs 1–3 months
Overall morbidity and mortality
Major early morbidity 32 (2.7 %)
Major late morbidity 12 (1 %)
30-day readmission rate 10 (0.8 %)
Late readmission rate 13 (1 %)
30-day mortality 2 (0.16 %)
Reoperations for failure 0 (0 %)
CPAP continuous positive airway pressure, BiPAP bilevel positive airway
pressure, PPIs proton pump inhibitors
a Only for preoperative CPAP/BiPAP users
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epigastric pain. All had risk factors such as Helicobacter
pylori (HP), and also (despite written and verbal warnings)
chronic ingestion of aggressive medications, as well as alco-
hol (distilled) and tobacco consumption; they were managed
conservatively.
Sporadic clinical reflux was reported by 26 patients
(2 %). The few episodes were associated with dietary trans-
gressions (always at night). Endoscopic studies revealed
the presence of some bile in the stomach with mild to mod-
erate pouch gastritis, but did not document any esophagitis.
Treatment included dietary and healthy life recommenda-
tions, continued FU by our nutritionists, PPIs (40 mg/day
for 6 months), and sucralfate (1 g before every meal and
before bedtime for 3 months, followed by 1 g before
bedtime for another 3 months). An upper GI endoscopy
was ordered afterwards; all patients healed or significantly
improved. Depending on their course, FU endoscopic stud-
ies were performed annually in some patients. Moreover, at
completion of a 5-year FU, we planned screening endo-
scopic studies for all patients and were able to obtain them
in 265 (22 %). Most other patients were completely asymp-
tomatic and did not want the study. There were no signifi-
cant findings; importantly, there were no cases of esopha-
geal reflux and/or esophagitis or signs of acute or chronic
stomal or MU. Mild to moderate pouch gastritis was found
in 21 (8 %) and presence of HP in 9 (3.4 %). These patients
were treated as those with clinical reflux (see above) and
HP eradication when needed.
Table 2 Complications and side effects following laparoscopic one-anastomosis gastric bypass (OAGB) in 1200 morbidly obese patients
n (%) Treatment/comments
Intraoperative complications requiring conversion to open surgery 4 (0.3)
Intra-abdominal bleeding 2 (0.16) LSML
EG junction perforation (calibration tube) 1 (0.08) LSML (conversion to distal RYGB)
Incorrect gastric transection 1 (0.08) LSML (conversion to distal RYGB)
Immediate postoperative complications resolved by open
reoperations
6 (0.5)
Intra-abdominal bleeding 2 (0.16) LSML
Leaks (anastomotic/gastric reservoir) 2 (0.16) LSML/one with prosthesis (placed radiologically)
Small bowel obstruction 1 (0.08) LSML/afferent limb torsion
Partial necrosis of excluded stomach 1 (0.08) LSML/patient died with nosocomial pneumonia
Immediate postoperative complications resolved by re-laparoscopy 10 (0.8)
Intra-abdominal bleeding 7 (0.58) Solved laparoscopically
Leak (anastomotic/gastric reservoir) 1 (0.08) Solved laparoscopically/prosthesis (placed endoscopically)
Small bowel obstruction 1 (0.08) Solved laparoscopically/adhesion (trocar incision-efferent limb)
Acute dilation excluded stomach 1 (0.08) Solved laparoscopically
Early postoperative complications resolved conservatively 12 (1)
Leaks (anastomotic/gastric reservoir) 10 (0.83) Medical treatment (NPO and TPN)/endoscopic prostheses placed
in two
Acute (postoperative) pancreatitis 1 (0.08) Submitted to laparoscopic OAGB and cholecystectomy
Infected hematoma 1 (0.08) Percutaneous drainage
Major late complications 12 (1)
Gastroenteric (stomal) stenosis 6 (0.5) Pneumatic endoscopic dilation (5), endoscopic coated prosthesis
(1)
Anastomotic or marginal ulcer 6 (0.5) Medical treatment/acute UGI bleed (5), chronic persistent pain (1);
all had risk factors
Other complications and side effects
Espohageal clinical reflux 26 (2) Medical treatment
Malnutrition (protein) 14 (1.1) Medical treatment/two readmitted for IV supplementation
Severe iron deficiency anemia 15 (1.25) Medical treatment (parenteral iron)
Mild iron deficiency anemia Up to 30 % Medical treatment (oral iron)
Nausea/vomiting 6 (0.5) Early readmission and medical treatment
Hair loss/iron/folate/B12 deficiencies Variable Medical treatment/improvement after intestinal adaptation
Diarrhea/bad fecal odor Variable Medical treatment/improvement after intestinal adaptation
LSML left subcostal mini-laparotomy, RYGBRoux-en-Y gastric bypass, EG esophago-gastric,NPO nil per os, TPN total parenteral nutrition,UGI upper
gastrointestinal, IV intravenous
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Preoperative nutritional deficits were found in some pa-
tients including iron (∼10%), vitamin D (∼15%), and calcium
(∼4 %). After OAGB, a few patients developed excessive WL
and/or nutrient deficits (usually within the first 2–3 postoper-
ative years). Table 3 depicts the percentage of patients with
specific deficiencies (values below normal range) at different
points in time during our FU.Most were controlled and treated
on an ambulatory basis and recovered with dietary recommen-
dations and once intestinal adaptation was complete.
However, a total of 14 patients (1.2 %) required further treat-
ment for hypoalbuminemia; all received high-protein enteral
supplements and pancreatic enzymes (Kreon®-Abbott,
Germany) 10,000–25,000 IU with each meal during at least
3 to 6 months; 2 were readmitted and managed with IValbu-
min. Iron deficiency was rather common, especially in fertile
women with copious menstrual bleeding. Up to one third re-
quired oral supplements beyond the expected time for intesti-
nal adaptation, and 15 patients (1.3 %) required parenteral
iron. Among liposoluble vitamins, vitamin D insufficiency
was present in more than half of our patients at 3 years and
one third in the long term; this required continuous supple-
mentation in ∼20 % of them. Longer supplementation was
also needed for vitamins A and K in ∼3 and 0.5 %, respec-
tively. Deficits in hydrosoluble vitamins were basically found
in B9 (folic acid) and B12; supplements were needed in ∼15 %
at 3 years and 2 % in the longer term. An initial higher rate
found in B9 (Table 3) was probably a reflection of preopera-
tive deficiency. Calcium deficit was found in ∼8 % during the
first 2 years and decreased thereafter, but persisted in ∼2 % in
the longer term; supplements were especially recommended to
post-menopausal women. Zinc and copper were needed in ∼5
and 3 % in the long term only in women. Specific long-term
phosphorus, magnesium, andmanganese supplementation has
not been needed.
As in other malabsorptive procedures, soft stools, increased
bowel gas, and a bad fecal odor were present in most patients,
especially those consuming fatty and pure carbohydrate foods.
Bismuth salts, activated carbon, and simeticone usually con-
trolled symptoms well, and they usually improved progres-
sively with intestinal adaptation. These nutritional complica-
tions and side effects were not significantly different when
comparing our first 209 patients [5] to the more malabsorptive
group of patients operated on thereafter (see BOperative
Technique^).
The 30-day readmission rate was 0.8 % (10 patients). Two
had SBO and were reoperated on. All others were successfully
treated conservatively during 24–48 h; 6 had persistent nausea
and vomiting, 1 had a single episode of hematemesis and had
a stress ulcer at endoscopy, and 1 had an abstinence syndrome
from psychiatric medication with extreme anxiety. Late
readmissions were required in 13 patients (1 %) for stomal
stenosis (6), GI bleeding due to MU (5), and malnourishment
(2). Two patients died in this series (0.16 %); both had
superobesity, multiple comorbidities, and risk factors. One
suffered a pulmonary thromboembolism 3 days after BS
(without warning symptoms or additional postoperative com-
plications). The other suffered gastric wall necrosis, was
reoperated on, and developed refractory nosocomial pneumo-
nia. Both deaths occurred during the initial part of our series
[9], and there were no other casualties in >1000 patients op-
erated on thereafter.
Follow-Up, Weight Loss, and Quality of Life
Table 4 depicts the number of patients operated on per year; a
progressive increase was observed from 2002 to 2008. Also
shown is accrual of patients for FU either as in-office visits or
through electronic means. Although (as expected) there is a
gradual decrease in number available for this long-term FU, at
least 50 % of those operated on >12 years ago were being
followed up, and we had information from 7 out of 10 among
the whole group of 1200 patients. Our Bremote^ electronic FU
Table 3 Percentage of patients
with nutritional deficits (lab
values below normal) at different
point intervals after one-
anastomosis gastric bypass
(OAGB)
Interval after OAGB (months) 3 6 12 18 24 36 60 120
Vitamin/nutrient
A 0 0 0.9 1.8 1.6 2.1 0.8 0
D 18 21.4 32.3 19 38.3 54.9 45.7 32
E 0 0.2 0.1 0.1 0.2 0.1 0 0
K 0 0.1 0 0 0.3 0.5 0.1 0
B1 0 0.1 0.2 0 0 0 0 0
B6 0 0 0.2 0.2 0 0 0 0
B9 (folic acid) 32.5 17.6 18.6 24.1 22.2 18.2 9.8 2.3
B12 4.7 4 10.3 7.9 21.9 17.1 16.3 2.5
Iron 11.5 15.5 13.5 18.6 20.9 24.9 34.2 12.7
Calcium 4.3 8.1 6.7 5.6 2.9 1.3 2.1 1.9
Albumin 0.3 0.8 1.2 1 0.7 0.5 0.3 0
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reports were as objective as possible (see BPatients and
Methods^); overall, outcomes for this group were not signif-
icantly different from those found in patients seen directly at
our office. During this FU period, 15 (1.25 %) patients died
from unrelated causes; these included aviation and auto acci-
dents (4), lung cancer (2), surgical complications from unre-
lated operations several years after OAGB (2), family aban-
donment and suicide (2), myocardial infarction 5 years after
OAGB (1), complicated appendicitis (1), complicated
Guillain-Barre syndrome (1), unspecified autoimmune disease
(1), and prostate cancer (1).
Depending on initial (preoperative) EW, patients lost a
mean of ∼15–20 kg in the first month and ∼30–40 kg in the
first trimester. Table 5 outlines evolution of WL expressed in
various forms at different point intervals. The number and
percentage of patients followed up at each time interval are
included; only from 13 % (at 6 years) to 30 % (at 12 years) of
our cumulative number of patients were lost for FU.
Substantial WL was documented for most patients; through
time, there was a slight weight increase in a few, which was
not clinically relevant. Thus, EWL was maintained in most of
our patients and according to Reinhold’s classification our
results ranged from good (EWL >50 %) to excellent (EWL
>75 %), and a long-term successful treatment (EWL >50 %)
was achieved in almost all patients.
The effect of OAGB on comorbidities is shown in Table 6.
The number of patients carrying each related disease preoper-
atively is included and varied widely. Figures in the columns
Bremission^ and Bimprovement^ represent what was recorded
at the last patient evaluation (either as in-office or electronic
FU). Severe metabolic comorbidities such as type II diabetes
mellitus, insulin resistance, hypertension, and sleep apnea ei-
ther totally resolved or substantially improved (most from the
first day after BS). Remission was also demonstrated in most
patients for other metabolic conditions like hyperlipidemia
and liver steatosis when the first biochemical tests were or-
dered at the 3rd postoperative month. Benefits were also evi-
dent for patients with Bmechanical^ complications related to
MO (osteoarthritis, urinary incontinence, and respiratory in-
sufficiency). Noteworthy is the fact that 53 % of our patients
had gastroesophageal reflux disease (GERD) of some degree
and all were relieved after the operation. Significant improve-
ment in QoL and in all but one IWQoL survey parameter was
found 3 months after BS. The item Bcomfort with food^ also
improved markedly but only 6 months after the operation;
moreover, problems with it were referred to as Binsignificant^












6 years (2008) 268 148 (55 %) 85 (32 %) 233 (87 %) 268 233 87
7 years (2007) 302 112 (37 %) 102 (34 %) 214 (71 %) 570 447 84
8 years (2006) 248 79 (32 %) 81 (33 %) 160 (65 %) 818 607 74
9 years (2005) 146 44 (30 %) 53 (36 %) 97 (66 %) 964 704 73
10 years (2004) 92 23 (25 %) 32 (35 %) 55 (60 %) 1056 759 72
11 years (2003) 86 17 (20 %) 34 (40 %) 51 (59 %) 1142 810 71
12 years (2002) 58 12 (21 %) 17 (29 %) 29 (50 %) 1200 839 70
Total 1200 435 (36 %) 404 (34 %) 839 (70 %)
a Cumulative
Table 5 Weight loss evolution
after one-anastomosis gastric by-





No. of patients (%)
Weight (kg)a BMI (kg/m2)a %EBMILa %EWLa
Preoperative 124 (82–308) 46 (33–86)
6 years (2008) 233 (87) 68 28.54 83.09 77
7 years (2007) 447 (84) 69 28.74 82.89 76
8 years (2006) 607 (74) 71 29.32 79.38 73
9 years (2005) 704 (73) 72 29.64 77.85 72
10 years (2004) 759 (72) 73 29.89 76.60 70
11 years (2003) 810 (71) 73 29.89 76.60 70
12 years (2002) 839 (70) 73 29.95 76.30 70
FU follow-up, BMI body mass index,%EBMIL percentage excess BMI lost,%EWL percentage excess weight lost
aMean
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at the 1-year office visit, when no patients reported food in-
tolerance of any kind. This improvement in QoL remained
through time.
Discussion
Widespread interest of specialists and demand from referring
physicians and patients have created a soaring increase in the
practice of BS. There are pros and cons in every operation; in
general, safety is inversely related to effectiveness. While
purely restrictive procedures have not proven to be effective
especially in achieving substantial long-term EWL and meta-
bolic benefits [15, 16], more complex malabsorptive opera-
tions have shown excellent EWL and remission of comorbid-
ities [16], but at the cost of long learning curves, more com-
plications, and less reproducibility [17]. As a mixed proce-
dure, RYGB has been considered by many the Bgold
standard^ [18] and was in fact our procedure of choice during
the open era and beginning of the laparoscopic one.
Laparoscopic RYGB, however, is a technically demanding
procedure with a relatively high morbidity and need for
reoperations (especially during its steep learning curve) [19].
Weight regain (WR) has also been an issue found in series
with a long-term FU [20].
When MGB was first reported [4], we embraced the possi-
bility of performing an operation with all benefits of a mixed
procedure with arguably less complexity. As others, we were
concerned about alkaline reflux and its potential consequences
and thus developed modifications in order to provide an
antireflux mechanism [5]. The scarcity of reports in MGB/
OAGB has changed. There are now several publications of
series [21–26], comparative studies [27–29], and RCT [30];
these types of studies have also been done with emphasis on
the metabolic syndrome [31–40], and there are even system-
atic and integrative reviews [41–44]. However, few groups
have studies of >1000 patients and most lack long-term FU;
hence, we decided to analyze the first 1200 consecutive pa-
tients in our experience, who were operated on between 2002
and 2008, thus completing a 6- to 12-year FU.
Perioperative Outcomes
Advantages ascribed to the procedure [4, 42–44] were evident
from the perioperative period in our patients (Table 1).
Recovery was usually quick and uneventful with rapid ambu-
lation, flatus passage, and almost no need for analgesics; this
led to a reduced LOS, which for our non-complicated cases
(97 %) has been one of the shortest reported thus far [42, 44].
Although OAGB provides reduced difficulty compared to
complex procedures, we believe it should not be promoted
as a very simple, easy, and rapid operation. Our OT varied
for each subgroup (Table 1), and was similar to other reports
[42], but definitely fell short compared to the original MGB’s
Bthirty minute case^ [4, 21]. Besides the fact that speediness is
not among our goals, several modifications in OAGB prove
time consuming.
Safety
As others [21–26, 42–44], we found OAGB to be a rather safe
operation. There were 32 (2.7%) early and 12 (1%) late major
complications (Table 2). Almost 70 % of the former were
treated conservatively or through re-laparoscopy, and all late
complications were treated conservatively. Specific analysis
led to interesting findings.
Early Complications
Leaks
Leaks were the most common complication. However, our
rate (1 %) is within range or lower than that of other MGB/
OAGB [42–44], RYGB [45], and laparoscopic sleeve
Table 6 Outcomes of one-
anastomosis gastric bypass
(OAGB) on comorbid conditions
in 1200 morbidly obese patients
Comorbidity No. with comorbidities (%) Remission (%) Improvement (%)
Type II diabetes mellitus 180 (15) 94 6
Fasting glucose impairment 216 (18) 100 –
Hypertension 387 (32) 94 6
Hyperlipidemia 673 (56) 96 4
Gastroesophageal reflux disease 636 (53) 92 8
Sleep apnea 1113 (93) 90 10
Osteoarthritis 1016 (85) 18 82
Urinary incontinence 60 (5) 22 78
Shortness of breath on exertion 1016 (85) 100 –
Fatty liver 1200 (100) 100 –
Polycystic ovarian disease 180 (15) – 100
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gastrectomy (LSG) series [46]. Experience was noted by a
decrease from 1.9 % in our first 209 patients [5] to 0.9 % in
those operated on thereafter. Most of them (77 %) were
managed conservatively; this is not common in other pro-
cedures, where leaks may be quite difficult to treat and
even fatal [16, 45]. Although some claim BP secretion in
the anastomotic region may result in leaks after MGB/
OAGB harder to manage [47], this did not happen. Since
there is no enteric sectioning and all intestinal arcade sup-
plies the area, blood flow in MGB/OAGB may hasten tis-
sue healing; also, a much longer pouch and OAGB’s
antireflux mechanism provide less mesenteric and vascular
traction (Fig. 1). These anastomotic characteristics may
have contributed to our favorable results with non-
operative treatment. A less conservative approach was re-
ported by Rutledge [21] who had a 1.1 % leak rate and all
patients were reexplored through laparoscopy. Chevallier
et al. [26] had 6 leaks (0.6 %); 3 were anastomotic, and all
were reoperated on. In contrast, Musella et al. [24] had 10
leaks (1 %). They divided them according to origin; all 5
gastric pouch leaks needed operative treatment, but 2 gas-
tric remnant and 2 of 3 anastomotic leaks were treated
conservatively. The lowest leak rate from large MGB/
OAGB series was reported by Kular et al. [25] with only
2 leaks in 1054 patients (0.1 %).
Bleeding
Intra-abdominal bleeding was the second most common com-
plication; its incidence (0.9 %) compares favorably with other
series [42, 44] and also decreased with time from 1.9 % [5] to
0.7 %. Intra-abdominal bleeding should be differentiated from
intraluminal GI bleeding. Chances for conservative and/or en-
doscopic management in the former are usually higher [24,
25]. Those with hemoperitoneum may be managed non-
operatively based on clinical grounds. Commonly, bleeding
ceases spontaneously and staple lines are assumed to be the
source [23].
Small Bowel Obstruction
In MGB/OAGB, there are no mesenteric defects to close, and
as most surgeons accustom [26, 28, 41–44], we did not close
Petersen’s defect. In spite of this, and as has been reported
[21–30, 42–44], there were no internal hernias. The only 2
cases (0.16 %) of SBO were due to other causes. This repre-
sents a great advantage compared to laparoscopic RYGB,
where internal hernias have been reported in up to 16 % of
patients [20]; some present many years after with symptoms
that range from simple chronic abdominal pain to frank bowel
necrosis, leading to difficulties for a timely diagnosis and
sometimes fatal outcomes [48].
Late Complications
Stomal Stenosis
All 6 (0.5 %) gastroenteric (stomal) stenosis presented during
the initial part of our series when anastomotic size ranged
from 1.5 to 2 cm. After increasing to ∼2.5 cm, we had no
further problems. All were successfully managed with pneu-
matic endoscopic dilations. Rate is within range of other
MGB/OAGB series and much better than most RYGB series
where strictures complicate up to 27 % of patients [49].
Although anastomotic tension, ischemia, and subclinical leaks
may cause these lesions, another potential contribution is that
standard RYGB includes a narrower (∼1.2 cm) anastomosis
[49]. Moreover, although most can be treated with endoscopic
dilations, up to a third may require a reoperation [50].
Marginal Ulcer
Critiques to MGB/OAGB emphasized it would lead to a
higher rate of MU and with less responsiveness to medical
management [47]. Recent systematic reviews report an inci-
dence of 0.6–4 % for large series [42, 44] which is less than
that found after RYGB which has a wide range between 0.6
and 25 % [51]. Various risk factors independent of bile reflux
(BR) have been identified [51]. Increased acid production in
an oversized pouch is a potential cause, and some hypothe-
sized presence of bile within the anastomotic area in MGB/
OAGB may actually have a protective effect buffering acid’s
ulcerogenic action [26]. Our MU rate of 0.5 % is one of the
lowest reported for any type of gastric bypass. Wemeticulous-
ly explain and stress avoidance of risk factors to our patients;
whether our antireflux mechanism had further beneficial ef-
fects is difficult to ascertain. Moreover, this longer FU dem-
onstrates they were as responsive to medical therapy as those
arising after RYGB. Our patients and those in most MGB/
OAGB series [26, 28, 42, 44] have responded to PPIs,
sucralfate, and HP eradication.
Bile Reflux
The main condemning argument against MGB/OAGB has
been the potential for BR and its consequences. This has been
dealt with thoroughly previously [24–28, 41–44]; gastric and
esophageal BR must be analyzed separately. Although BR to
the stomach may be frequent both physiologically [52] and
after some operations [53], symptomatic, endoscopic, and his-
tologic repercussions have neither been relevant nor conclu-
sively proven [54]. BR to the esophagus, on the other hand,
may have all, at least experimentally [55]. Although it was
common, and the main reason to abandon Mason’s loop
[56], MGB’s anatomical configuration makes esophageal
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BR highly improbable. Our OAGB (antireflux technique)
takes this a step further.
Symptomatic gastric and/or esophageal BR after MGB/
OAGB has been rare [26, 28, 41–44]. BR was referred by
2% of our patients. Symptoms were sporadic (2–3 times/year)
and included a bitter and/or sour sensation, sometimes
reaching the throat, usually at night after dietary transgres-
sions. Medical treatment was successful in all; to our knowl-
edge, no patient has been reoperated on elsewhere due to
Bintractable^ BR. Further seeking BR, we studied our first
20 patients with endoscopy and 24-h pHmetry, 12 and
18 months after BS; results were all normal [5]. We extended
this assessment and planned upper GI endoscopies for all
those reaching a 5-year FU. Almost 80 % did not accept,
mostly because they were completely asymptomatic.
Findings included mild to moderate pouch gastritis (8 %)
and HP (3 %), but there were no worrisome endoscopic or
histological changes.
Postoperative ancillary studies after MGB/OAGB have
been carried out by others. Chevallier et al. [57] found no
esophageal changes or significant findings in asymptomatic
patients. Musella et al. [24] performed endoscopies in 26
(3%) symptomatic patients with prolonged dyspepsia, epigas-
tric pain, heartburn, and vomiting and found anastomotic ul-
cers (1.7 %) and biliary gastritis (0.9 %), but no other signif-
icant finding. More recently, Tolone et al. [58] evaluated EG
junction function pre- and postoperatively through endoscopy,
high-resolution impedance manometry, and 24-h pH-imped-
ance monitoring; results were compared with patients submit-
ted to LSG. After MGB, there was no heartburn/regurgitation,
esophagitis, biliary gastritis, or presence of bile; also, mano-
metric patterns did not vary (from preoperative). Intragastric
pressure, GE pressure gradient, and reflux events (acid, weak-
ly acid, and evenweakly alkaline) all significantly diminished.
In contrast, due to the pylorus (functional obstruction), LSG
led to a significant elevation in all these parameters, and in
esophageal acid exposure. In fact, many consider LSG unsuit-
able for patients with GERD and/or Barrett’s esophagus [59];
reoperations for intractable GERD are not uncommon [60].
In contrast, reoperations after MGB/OAGB due to
Bintractable^ BR are rare, especially when standard operative
techniques are performed [26, 61, 62]; this has ranged from
0% (most series) to 0.7% [42, 44]. Critics have also published
reoperations due to BR [47]; however, as they accept, the
denominator in their series is not known.Moreover, in no case
has it been described exactly what Bintractability^ meant. It is
important to be familiar with postoperative phases of GI ad-
aptation to MGB/OAGB, so as not to blame BR as the culprit
of any dyspeptic symptom. Kular et al. [25] recently defined
BR after MGB as bilious vomiting and/or documented bile in
the esophagus on upper GI endoscopy with presence of
GERD-like symptoms, and proposed differentiating it from
vague symptoms that characterize Bdyspepsia.^ A clear
definition must be made in regard to symptoms, diagnostic
approach, and medical treatment before considering a reoper-
ation due to Bintractability.^ When needed, these latter have
included conversion to RYGB (with or without gastric pouch
shortening) and Braun entero-enterostomy [26, 47, 61, 62].
Since these few reoperations are usually performed in patients
who have already achieved significant EWL and metabolic
benefits, they are oftentimes technically not demanding and
very effective.
Bile Reflux and Gastroesophageal Cancer
The long-lasting association between gastric BR after gastrec-
tomy and gastric cancer has not been shared by many [63].
Recent comprehensive reviews conclude BR is only one of
many potential risk factors involved in gastric stump carcino-
ma [64]; these act as confounding variables which are difficult
to isolate to reach valid conclusions. Perhaps HP is the most
significant not considered in older studies [65]. Since GE can-
cer may appear 20 to 30 years postoperatively, the fact that it
has not been found after MGB/OAGB [41–44] may seem not
enough evidence. However, even the highly criticized and
abandoned Mason’s loop with its proven BR has not been
associated with esophageal cancer, and there is only one case
of gastric pouch cancer 26 years after [66]. The other 3 reports
of cancer after Mason’s loop were in the bypassed stomach
(not related to BR), and they have also been found after other
bariatric operations [67].
Cancer arising in the gastric pouch or esophagus has been
reported after BS [67], but never after MGB/OAGB. The only
case of cancer reported thus far also originated in the excluded
stomach in an Asian patient 9 years after MGB [68]. In spite
that in vitro bile in the esophagus can stimulate production of
inflammatorymediators and lead to changes in genetic expres-
sion to intestinal metaplasia [55], clinical studies have not
demonstrated an association between gastric bile and
Barrett’s esophagus [69]. Moreover, bile in the distal esopha-
gus in patients with GERD seems not to correlate with
Barrett’s esophagus as acid reflux does [70]. It is interesting
to note that in spite that LSG has been conclusively associated
with de novo or exacerbation of GERD [15], and GERD has
been proven to lead to Barrett’s esophagus and cancer [71],
MGB/OAGB has been the procedure under rigorous scrutiny
for a potential cancer risk, which so far has not been demon-
strated. Cancer in the distal esophagus has already been re-
ported not only after LSG but also after other BS including
RYGB [67].
Malabsortion/Malnutrition
Over time, we have progressively increased the extent of
bypassed SB from ∼200 cm to a range of 2.5 to 3.5 mts, based
both on total SB length and BMI (see BOperative
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Technique^). This Btailoring^ has also been performed by
other MGB/OAGB surgeons [22, 23, 34]. Although increased
malabsorption could theoretically lead to more side effects
and malnutrition, only 14 (1.1 %) patients suffered protein
malnutrition. This rate is comparable to that reported in other
MGB/OAGB [26, 28, 42, 44] and RYGB series [20]. Our
strict postoperative regimen may have contributed to these
figures, and not surprisingly all those with protein malnutri-
tion admitted not following our program.
Malabsorption is only one of many factors that lead to
malnutrition; among others, these include psychologic, per-
sonal, family, social, and even economic. Malnutrition can
thus be seen after procedures which entail none or less
malabsorptive components [20, 72, 73]. In our experience,
malnutrition has been temporary; after our support program
including IV therapy followed by a strict program of enteral
supplementation and counseling (aimed at improving all other
factors that influence nutritional status), and once intestinal
adaptation is reached [74], it has posed no further problems.
Long-term albumin therapy has not been required, and so far,
we have not documented any case needing reversal or conver-
sion to other operations for this reason in our group.
Chevallier et al. [26] have also not reversed any patient but
report malnutrition in 2 (0.2%) whowere under evaluation for
a reoperation. They also noted deficiency problems always
involved noncompliant patients. In the very few cases of
reoperations reported by others, alternatives have included
reversal to a normal anatomy or conversion to LSG. In his
larger study, Rutledge [21] reported excessive WL in 1 %
and selected reversal as their reoperation of choice. Lee et al.
[61] revised 23 of 1322 patients (1.7 %); the most common
cause was malnutrition in 9 (0.7 %). They recommended con-
version to LSG due to efficacy in improving malnutrition
without regaining body weight. Noun et al. [23] reported ex-
cessive WL in 4 (0.4 %) patients with reversal in 2 and con-
version to LSG in the other 2. The Italian group [24] submitted
7 of 818 patients (0.8 %) to late reoperations; indication was
EWL > 100 % in only one (0.1 %). All these groups agree a
laparoscopic approach with its attendant benefits in this kind
of reoperations was feasible and technically not demanding.
Other Complications and Side Effects
Iron deficiency anemia (IDA) has been rather common after
any type of gastric bypass [72, 73]. Although we originally
published rates of 1 % in severe IDA (requiring parenteral
iron) and 7 % in moderate IDA (needing oral iron) [5], figures
increased to 1.25 % and up to 30 %, respectively, after this
longer FU. Hair loss and mild deficiencies in micronutrients
were noted during the first months but usually subsided once
intestinal adaptation was reached. Very few patients required
supplementation beyond this time (especially of folate, calci-
um, and vitamin B12). Since almost half of our patients came
from northern Spain where sunlight is limited, vitamin D has
been a common deficit both pre- [75] and postoperatively.
Supplementation is currently started prior to OAGB and is
continued long term in up to 20 % of those patients.
In regard to other GI side effects, nausea and vomiting were
rare, but we did have to readmit 6 (0.5 %) patients for medical
treatment and reassurance in the early postoperative period.
As in other MGB/OAGB series [26, 28, 42, 44], dumping was
uncommon. Permanent contact of food with BP secretions
leading to a slower absorption of sugars may be a plausible
explanation which would need further studies for confirma-
tion [73]. When present, symptoms were transient and well
controlled with dietary adjustments. This contrasts with
RYGB where dumping is quite common and even considered
an asset in order to limit a patient’s consumption of sugars and
carbohydrates, but may end up as a considerable problem
affecting digestive comfort and QoL [76].
Efficacy
Weight Loss
OAGB had a greater WL compared to any purely restrictive
operation [3, 15, 16], standard RYGB [3, 16, 20], and even
some series of MGB [42, 44]; WL curves were steeper, fre-
quently reaching ideal weight, and similar results to those
obtained with more complex malabsorptive techniques [3,
16]. Once WL stabilized, it was maintained through the years
in most patients, with only subtle increases in some.
Substantial WR requiring a reintervention was not evident in
this series. Although inadequate EWL and/or considerable
WR is especially seen in patients submitted to purely restric-
tive techniques [3, 15, 16], RYGB series with a long-term FU
have reported them in ∼35% and up to 20%, respectively [20,
77]. This has led to modifications such as banded RYGB [78]
and distal RYGB [79] in order to optimize EWL and its dura-
bility. Comparative studies have demonstrated superior effica-
cy of MGB/OAGB in terms of WL when compared to LSG
[28], and either similar or greater WL when compared to
RYGB [27, 29, 30].
Resolution of Metabolic and Other Comorbidities
Both MGB and OAGB comprise characteristics which are
common in metabolic surgery. These include some form of
restriction, and a long BP limb which bypasses the proximal
gut and places food in the distal SB [80]. Its metabolic effect in
our series was outstanding (Table 6) and similar to results
obtained by others [31–40]. Metabolic comorbidities im-
proved immediately and most subsided during the following
weeks; this was corroborated clinically and biochemically
during our FU. Once WL was being achieved, other
Bmechanical^-related comorbidities were also abated. We
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recently published results from selected patients included in
the IFSO-European Accreditation Council (EAC) for Centers
of Excellence database with insulin resistance/type 2 DM [32]
or lipid profile derangements [36]. Substantial WL and signif-
icant improvement or full remission from their metabolic con-
dition was observed in both series. Overall, comparative stud-
ies and RCT favor MGB/OAGB over purely restrictive oper-
ations and are similar to RYGB in their metabolic benefits
[37–40].
Follow-Up
Poor FU is definitely the BAchilles heel^ in all BS. Since most
patients came from different parts of our country, direct in-
office consultation is difficult to accomplish. Nonetheless, we
have been able to physically see >1/2 and >1/5 of our patients,
6 and 12 years after the operation, respectively (Table 4).
Since our referral pattern was evident to us from the begin-
ning, we strove to keep close contact with our patients through
telephone or electronic means; also, Bremote^ reports have
been as objective as possible and include all information that
would be obtained directly at the office including photo-
graphs, questionnaires, and full biochemical tests.
Certification by the IFSO-EAC as a Centre of Excellence
and their rigorous and increasing requisites for recertification
have validated our methods and continually support and guide
our efforts to improve overall FU. The IFSO-EAC database
indeed serves as the registry some colleagues have strongly
recommended in order to have better insight in regard to this
operation [47]. With all these resources, we have been able to
gather information from ∼70 % of our patients through this
long-term FU (Table 4).
Name of the Procedure—a Final Controversy
A highly criticized concept, when initially proposed, is steadi-
ly being accepted worldwide. Centers of more than 25 coun-
tries are now performing it [81]. This has brought about a
controversy regarding the name for the procedure, which has
led to unfortunate confusions [82]. We recently presented our
arguments on why we support views of others in considering
OAGB as the only standing alternative name for MGB, in
order to reconcile terms and facilitate issues in publishing
future related courses and communications [83]. This was
further supported at the 2015 IFSO meeting in Vienna where
the academic MGB-OAGB International Club was founded
[84]. We call again on the various bariatric teams that are
performing the original MGB or our modified version, the
OAGB, to aid in the dissemination and acceptance of this
procedure by presenting and publishing their experiences
and standardizing the name (to MGB/OAGB), in order for
all of us to be recognized as a whole. Now that many of its
controversies are being surpassed and the bariatric surgical
community is accepting the procedure as a rational alternative
in the bariatric repertoire, we should make all efforts in order
to conciliate in regard to the name, avoid new disagreements,
and work towards making MGB/OAGB mainstream in obe-
sity and metabolic surgery.
Conclusions
This group represents the original largest series, and with the
longest FU of patients submitted to the so-called OAGB or
BAGUA (bypass gástrico de una anastomosis—in Spanish), a
modification of the MGB. It is also one of the largest series
with longer FU among all centers performing the MGB/
OAGB concept. OAGB provides reduced difficulty and oper-
ating time, and very low morbidity and mortality. Alkaline
reflux (clinical and endoscopic) is very infrequent, mild, and
treatable. Concerns regarding BR and its potential conse-
quences currently seem unsubstantiated but await studies with
even longer-term outcomes. So far, development of subse-
quent cancer has not been reported. Long-term substantial
EWL, remission of comorbidities through its metabolic bene-
fits, and degree of satisfaction are similar to the best results
obtained with more aggressive and complex operations.
OAGB is a safe and effective powerful alternative which is
slowly (but surely) becoming mainstream in bariatric surgery.
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